The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 18, 2024
Filed:
Aug. 06, 2019
Applicant:
The U.s.a., As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);
Inventors:
Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C12N 15/86 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); A61K 47/6829 (2017.08); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C12N 15/86 (2013.01); G01N 33/5748 (2013.01); A61K 2039/505 (2013.01);
Abstract
Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.